0HS8.IL,0P0001HAF4,200 (0HS8.IL)
- GlobeNewswire
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in September: H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024)Format: VirtualPresentation: Available on-demand beginning Monday, S
- GlobeNewswire
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma. “Cholangiocarcinoma is a rare and aggressive form of cancer that present
- Simply Wall St.
Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
